Table 6.
InterLymph pooled estimates of associations for selected risk factors, and the same estimates from the Mayo Case-Control Study (Phases 1-2)
| InterLymph Pooled Estimates |
Mayo Case-Control Study (Phases 1-2)† |
|||||||
|---|---|---|---|---|---|---|---|---|
| Exposure and Reference | Mayo in Published Analysis?* | N studies | Cases/controls | Exposure Category | OR | (95% CI) | OR | (95% CI) |
| Smoking [30] | No | 9 | 6594/8892 | Never smoker | 1.00 | (reference) | 1.00 | (reference) |
| Ever | 1.07 | (1.00-1.15) | 1.10 | (0.91-1.33) | ||||
| Current | 1.10 | (1.00-1.20) | 1.03 | (0.68-1.56) | ||||
| Pack-years | ||||||||
| 1 to 10 | 0.99 | (0.90-1.08) | 1.12 | (0.84-1.49) | ||||
| 11 to 20 | 1.04 | (0.93-1.17) | 0.95 | (0.66-1.35) | ||||
| 21 to 35 | 1.14 | (1.02-1.27) | 1.02 | (0.71-1.45) | ||||
| 36+ | 1.21 | (1.09-1.34) | 1.25 | (0.91-1.71) | ||||
| Duration (years) | ||||||||
| 1 to 10 | 0.94 | (0.84-1.06) | 1.30 | (0.93-1.81) | ||||
| 11 to 20 | 1.02 | (0.91-1.13) | 0.95 | (0.68-1.33) | ||||
| 21 to 35 | 1.12 | (1.02-1.23) | 0.97 | (0.73-1.29) | ||||
| 36+ | 1.16 | (1.05-1.28) | 1.33 | (0.97-1.83) | ||||
| Alcohol [29] | No | 9 | 6492/8683 | Never drinker | 1.00 | (reference) | 1.00 | (reference) |
| Ever drinker | 0.83 | (0.76-0.89) | 0.84 | (0.61-1.14) | ||||
| Current drinker | 0.73 | (0.64-0.84) | 0.81 | (0.59-1.11) | ||||
| Former drinker | 0.95 | (0.80-1.14) | 0.99 | (0.68-1.45) | ||||
| Frequency for ever (servings/week) | ||||||||
| 1 to 6 | 0.81 | (0.74-0.88) | 0.88§ | (0.68-1.13) | ||||
| 7 to 13 | 0.83 | (0.74-0.92) | ||||||
| 14 to 27 | 0.85 | (0.76-0.95) | 0.82 | (0.63-1.06) | ||||
| 28+ | 0.87 | (0.76-0.99) | 0.65 | (0.46-0.90) | ||||
| Family History [31] | Yes | 11 | 10211/11905 | No Family Hx | 1.0 | (reference) | 1.00 | (reference) |
| NHL | 1.5 | (1.2-1.9) | 1.92 | (1.23-3.01) | ||||
| Any Heme | 1.5 | (1.3-1.6) | 2.20 | (1.62-2.98) | ||||
| Autoimmune Diseases [32] | No | 12 | 12982/16441 | SLE | 2.69 | (1.68-4.30) | 1.79 | (0.39-8.14) |
| Sjogren | 6.56 | (3.10-13.9) | 5.70 | (1.18-27.5) | ||||
| RA | 1.06 | (0.87-1.29) | 1.26 | (0.85-1.87) | ||||
| Obesity [33] | Yes | 18 | 10453/16507 | <18.5 | 0.88 | (0.71-1.08) | 1.05 | 0.42-2.62 |
| 18.5-24.99 | 1.00 | (reference) | 1.00 | (reference) | ||||
| 25-29.99 | 0.95 | (0.85-1.07) | 0.97 | 0.77-1.22 | ||||
| 30-39.99 | 0.97 | (0.81-1.15) | 1.11 | 0.86-1.44 | ||||
| 40+ | 0.99 | (0.70-1.41) | 0.64 | 0.33-1.27 | ||||
| Atopy [34] | Yes | 13 | 13535/16388 | Asthma | 0.97 | (0.84-1.11) | 0.95 | (0.69-1.29) |
| Eczema | 1.04 | (0.87-1.25) | 1.12 | (0.94-1.32) | ||||
| Any allergy | 0.80 | (0.68-0.94) | 1.20 | (0.97-1.48) | ||||
| SNPs‡ [35] | Yes | 14 | 7999/8452 | TNF -308G>A (rs1800629) | ||||
| GG | 1.00 | (reference) | 1.00 | (reference) | ||||
| AG | 1.12 | (1.04-1.21) | 1.00 | (0.74-1.34) | ||||
| AA | 1.34 | (1.10-1.62) | 2.14 | (0.94-4.85) | ||||
| AG/AA | 1.14 | (1.06-1.23) | 1.08 | (0.81-1.43) | ||||
| LTA 252A>G (rs909253) | ||||||||
| AA | 1.00 | (reference) | 1.00 | (reference) | ||||
| AG | 1.01 | (0.94-1.09) | 1.11 | (0.84-1.47) | ||||
| GG | 1.12 | (1.00-1.27) | 1.20 | (0.77-1.85) | ||||
| AG/GG | 1.04 | (0.96-1.11) | 1.13 | (0.87-1.47) | ||||
| IL10 1082A>G (rs1800896) | ||||||||
| AA | 1.00 | (reference) | 1.00 | (reference) | ||||
| AG | 1.06 | (0.97-1.14) | 1.06 | (0.77-1.46) | ||||
| GG | 1.08 | (0.98-1.19) | 0.87 | (0.59-1.26) | ||||
| AG/GG | 1.06 | (0.98-1.15) | 0.99 | (0.73-1.35) | ||||
*
Phase 1 Mayo case-control data included in the pooled analysis.
†
Adjusted for design variables (age, sex and geographic region).
§
Estimate is for 1-13 servings/week.
‡
Phase 1 Mayo data only.